Selected article for: "disease SARS infection and early diagnosis"
Author: Lai, Samuel K.; McSweeney, Morgan D.; Pickles, Raymond J.
Title: Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19
  • Cord-id: q5nws0q8
  • Document date: 2021_1_10
    • ID: q5nws0q8
    Snippet: COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We pr
    Document: COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh nebulizers as a promising approach for the treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • active mechanism and acute respiratory: 1, 2, 3, 4
    • acute respiratory and additional period: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory and low airway: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory and low dosage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory and low respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory disease syndrome and administration route: 1, 2
    • acute respiratory disease syndrome and low affinity: 1
    • acute respiratory disease syndrome and low airway: 1, 2
    • acute respiratory disease syndrome and low dosage: 1, 2